S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:BCTX

BriaCell Therapeutics Stock Forecast, Price & News

$6.26
-0.24 (-3.69%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.00
$6.48
50-Day Range
$6.50
$10.61
52-Week Range
$2.81
$12.47
Volume
956,092 shs
Average Volume
875,168 shs
Market Capitalization
$99.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.87
30 days | 90 days | 365 days | Advanced Chart
Receive BCTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCTX
Employees
147,000
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.75 per share

Profitability

Net Income
$-430 thousand
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$99.83 million
Optionable
Not Optionable

Company Calendar

Last Earnings
12/14/2021
Today
1/25/2022
Next Earnings (Estimated)
3/30/2022
Fiscal Year End
7/31/2022

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1412th out of 1,416 stocks

Pharmaceutical Preparations Industry

684th out of 684 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












BriaCell Therapeutics (NASDAQ:BCTX) Frequently Asked Questions

When is BriaCell Therapeutics' next earnings date?

BriaCell Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for BriaCell Therapeutics
.

How were BriaCell Therapeutics' earnings last quarter?

BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced its quarterly earnings data on Tuesday, December, 14th. The company reported ($0.15) earnings per share for the quarter.
View BriaCell Therapeutics' earnings history
.

Who are BriaCell Therapeutics' key executives?

BriaCell Therapeutics' management team includes the following people:
  • William V. Williams, President, Chief Executive Officer & Director
  • Gadi Levin, Chief Financial Officer & Secretary
  • Miguel A. Lopez-Lago, Senior Director-Research & Development
  • Farrah Dean, Manager-Corporate Development & IR Contact

When did BriaCell Therapeutics IPO?

(BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is BriaCell Therapeutics' stock symbol?

BriaCell Therapeutics trades on the NASDAQ under the ticker symbol "BCTX."

Who are BriaCell Therapeutics' major shareholders?

BriaCell Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Concord Wealth Partners (0.08%), National Bank of Canada FI (0.00%) and Cutler Group LP (0.00%).

Which major investors are buying BriaCell Therapeutics stock?

BCTX stock was purchased by a variety of institutional investors in the last quarter, including Concord Wealth Partners, National Bank of Canada FI, and Cutler Group LP.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BriaCell Therapeutics' stock price today?

One share of BCTX stock can currently be purchased for approximately $6.26.

How much money does BriaCell Therapeutics make?

BriaCell Therapeutics has a market capitalization of $99.83 million.

How many employees does BriaCell Therapeutics have?

BriaCell Therapeutics employs 147,000 workers across the globe.

What is BriaCell Therapeutics' official website?

The official website for BriaCell Therapeutics is www.briacell.com.

Where are BriaCell Therapeutics' headquarters?

BriaCell Therapeutics is headquartered at 3RD FLOOR BELLEVUE CENTRE 235-15TH STR, WEST VANCOUVER A1, V7T 2X1.

How can I contact BriaCell Therapeutics?

BriaCell Therapeutics' mailing address is 3RD FLOOR BELLEVUE CENTRE 235-15TH STR, WEST VANCOUVER A1, V7T 2X1. The company can be reached via phone at (604) 921-1810 or via fax at 604-921-1898.


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.